1,439 results on '"Melero, Ignacio"'
Search Results
2. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
3. Central Role of the Antigen-Presentation and Interferon-γ Pathways in Resistance to Immune Checkpoint Blockade
4. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma
5. Weakly supervised deep learning to predict recurrence in low-grade endometrial cancer from multiplexed immunofluorescence images
6. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
7. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
8. Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma
9. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy
10. Intratumoral administration of mRNA encoding IL-12-based immunocytokines targeting CSF1R and PD-L1 exert potent antitumor effects while restraining systemic exposure to IL-12
11. Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists and TGF-β antagonists.
12. Cancer vaccines: the next immunotherapy frontier
13. Low-dose ionizing γ-radiation elicits the extrusion of neutrophil extracellular traps
14. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
15. Supplementary Methods S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
16. Supplementary Figure S2 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
17. Supplementary Table S1 from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
18. Data from Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
19. Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C
20. Charting roadmaps towards novel and safe synergistic immunotherapy combinations
21. Neutrophil Extracellular Traps, Local IL-8 Expression, and Cytotoxic T-Lymphocyte Response in the Lungs of Patients With Fatal COVID-19
22. Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic
23. Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021
24. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
25. Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus
26. Overcoming the limitations of cytokines to improve cancer therapy
27. Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment
28. Omentum: Friend or foe in ovarian cancer immunotherapy?
29. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
30. The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy
31. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
32. Intratumoural administration and tumour tissue targeting of cancer immunotherapies
33. Advances in immunotherapy for hepatocellular carcinoma
34. Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
35. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
36. Diverse immune environments in human lung tuberculosis granulomas assessed by quantitative multiplexed immunofluorescence
37. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
38. Prognostic value of macrophage polarization markers in epithelial neoplasms and melanoma. A systematic review and meta-analysis
39. Interleukin-18 in cancer immunology and immunotherapy
40. The significance of the omentum in locoregional immunotherapy for peritoneal carcinomatosis
41. Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis
42. 617 A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors
43. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming
44. Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies
45. Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014
46. CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
47. Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms
48. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
49. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
50. Dendritic cells in cancer immunology and immunotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.